Navigation Links
UofL awarded $9.56 million to form first-ever multicenter cardiovascular research network
Date:2/4/2011

LOUISVILLE, Ky. The National Heart, Lung and Blood Institute has awarded $9.56 million over five years to a University of Louisville Health Sciences Center research scientist to form a multi-center network examining cardioprotective therapies at the preclinical level.

Dr. Roberto Bolli, director of the Institute of Molecular Cardiology and chief of the Division of Cardiovascular Medicine at UofL, is principal investigator of the "CAESAR Project" a consortium for preclinical assessment of cardioprotective therapies that will involve laboratories at UofL, Johns Hopkins University in Baltimore, Emory University in Atlanta and Virginia Commonwealth University in Richmond.

The four-center project marks the first time the National Institutes of Health has funded a network of laboratories to test cardioprotective therapies at the preclinical level using the same scientific rigor as applied in clinical trials.

The multi-center network being established will be available to all investigators in the nation so that data can be shared with the goal of ultimately translating this type of basic research into clinically applicable therapies for patients with acute myocardial infarction, Bolli said.

Specifically, the researchers will perform blinded, randomized animal studies to examine how to lessen the damage done to heart muscle in a heart attack. An estimated 1.3 million Americans have a myocardial infarction a heart attack each year. The prognosis of these patients is dependent upon the size of the infarct the larger the infarct, the greater the likelihood of subsequent heart failure and death. Also, the damage done to the heart is irreversible; once heart muscle is lost to an infarct, it is dead tissue that cannot be reclaimed.

For almost 40 years, the NIH/NHLBI has invested considerable resources in preclinical studies aimed at developing infarct-sparing therapies. Throughout this time, hundreds of therapies have been developed that have been claimed to limit infarct size in preclinical models. However, Bolli said, none have advanced to the clinical stage.

"This enormous investment at least several hundred million dollars over the past 40 years has not produced any notable clinical application. Results have generally not been replicated in from one lab to another, and no cardioprotective therapy is currently available for clinical use," Bolli said. "Approximately eight years ago, I began talking with NIH representatives about the need to change how we are conducting cardioprotective preclinical studies. Those conversations have led to this grant."

One key change in how these studies are conducted is the addition of a statistician in developing the research study design. Another is ensuring reproducibility; each study will be performed in two centers using identical protocols, with each center unaware of the other's results.

The goal of the project is to identify therapies that are proven to work through rigorous study in preclinical models and ultimately advance them to clinical trial stage.

"CAESAR will be a major paradigm shift in cardioprotection. By screening promising therapies and identifying those that are truly effective in relevant experimental models and thus, are most likely to be ultimately effective in patients CAESAR will focus clinical trials on those therapies and will dramatically advance our ability to rationally translate basic findings into clinical trials," Bolli said.

"Dr. Bolli's career continues to be distinguished by his efforts to develop innovative solutions for fighting heart disease, the leading cause of death in the United States," said Dr. James R. Ramsey, president of the University of Louisville. "By conceiving, creating and leading this network Dr. Bolli demonstrates daily how the people at the University of Louisville strive to find ways to improve the lives of people in Kentucky and beyond."

Joining Bolli in the research at UofL are Dr. Xian-Liang Tang, associate professor of medicine, Dr. Yiru Guo, associate professor of medicine, Dr. Qianhong Li, assistant professor of medicine, and Dr. Steven Jones, associate professor of medicine, all with the Division of Cardiovascular Medicine in the Department of Medicine; and Dr. Maiying Kong, associate professor of bioinformatics and biostatistics in the School of Public Health and Information Sciences.

Leading the efforts at the other university centers are Dr. Charles Steenbergen at Johns Hopkins; Dr. David Lefer and Dr. Jakob Vinten-Johansen at Emory; and Dr. Rakesh Kukreja at Virginia Commonwealth.


'/>"/>

Contact: Jill Scoggins
jill.scoggins@louisville.edu
502-852-7461
University of Louisville
Source:Eurekalert

Related medicine news :

1. San Diego Unified School District Awarded Silent Hero Grant From got breakfast?(R) Foundation
2. $250,000 grant awarded for groundbreaking ligament and tendon repair research
3. $250,000 Grant Awarded for Groundbreaking Ligament and Tendon Repair Research
4. $300,000 CIHR grant awarded to Medicago, the Research Institute of the MUHC and McGill University
5. Hard to Treat Diseases (HTDS) Awarded Two Antibiotics Certificates For Chile
6. MEDNET and Hielix Awarded the State of North Dakota Contract for Statewide Health Information Exchange (HIE) Strategic and Operational Plans
7. Centenes Arizona Behavioral Health Unit Awarded Expanded Contract
8. Bloomberg School of Public Health awarded $15 million for laboratory renovation and modernization
9. New York College of Osteopathic Medicine (NYCOM) at NYIT Awarded $1 Million Federal Grant
10. Kineta Awarded NIH Grant to Complete Preclinical Studies on Type 1 Diabetes / Multiple Sclerosis Drug Candidate
11. Canadian research team awarded international grant for work on Indigenous peoples health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Love is ... roses in a variety of colors, assortments and packaging. This staple for Valentine’s Day ... King Kullen location. , For Valentine’s Day, not only are long-stem roses available, ...
(Date:2/5/2016)... Falls, NY & Salt Lake City, UT (PRWEB) , ... February ... ... Davis, Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with ... on the New Really Cool Humans Amateur TV Network. , Each week, on his ...
(Date:2/5/2016)... ... ... The event is being held on April 7, 2016 from 5:30 p.m. to ... will fund nearly $100,000 for research for the care and cure of Parkinson’s disease. ... the architect of this informative event to raise awareness and funds for Parkinson’s. ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco ... micro-needling services in their Napa Valley office. The technique utilizes the body’s own ... Dr. Canales and Dr. Furnas, are part of only a select few cosmetic ...
(Date:2/5/2016)... Dickson, Tennessee (PRWEB) , ... February 05, 2016 ... ... State Community College President George H. Van Allen have signed a joint enrollment ... semester, provides a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)...  Montoya Love is recognized by Continental Who,s Who ... Montoya is the Regulatory Systems Operations Manager with ... Manufacturing and selling a broad range of ... healthcare institutions, clinical laboratories and life science researchers with ... globe. ...
(Date:2/4/2016)... 2016  Omnicell, Inc. (NASDAQ: OMCL ), a leading ... systems, today announced results for its fiscal year and ... --> GAAP results: Revenue for the ... million or 4.1% from the third quarter of 2015, ... quarter of 2014. Revenue for the year ended December 31, ...
(Date:2/4/2016)... , Feb. 4, 2016  AMRI (NASDAQ:  AMRI) today ... of Pfizer Inc. and President of Pfizer Global Supply, has ... of February 4, 2016. In addition, the Company announced that ... the audit committee since 2010, has retired from the AMRI ... attention to his other business ventures.  William ...
Breaking Medicine Technology: